Skip to content
‹ Back to IndustriesSciences

SpaceX Successfully Launches the Falcon Heavy Rocket

SpaceX launched Falcon Heavy on Feb. 6, sending a Tesla Roadster into orbit and landing two of three core boosters, a successful test run for future space exploration and travel.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from Spacex on MarketScale.

By Sciences · · Promoted Content
Share
SpaceX Successfully Launches the Falcon Heavy Rocket

Key takeaways

01

Elon Musk has made it his life mission to take humankind to space.

02

On February 6th, he got even closer to achieving that goal when his company SpaceX launched the historic maiden voyage of its Falcon Heavy Rocket, putting a Tesla Roadster into orbit, and landing two rocket boosters back on Earth.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Elon Musk has made it his life mission to take humankind to space. On February 6th, he got even closer to achieving that goal when his company SpaceX launched the historic maiden voyage of its Falcon Heavy Rocket, putting a Tesla Roadster into orbit, and landing two rocket boosters back on Earth. After a brief two-hour delay, the launch departed from Kennedy Space Center in Cape Canaveral, Florida—the same location from which NASA’s Apollo moon missions and space shuttles departed from.

The rocket itself is impressive. It stands at a massive 23 stories tall and is powered by 27 engines on three core boosters, which produces 5 million lbs. of thrust at liftoff. SpaceX, ever the innovator in composite applications, engineered the rocket’s payload fairing with a composite structure and carbon fiber face sheets that were manufactured in-house. It’s built to protect satellites during delivery to low-Earth orbit as well as geosynchronous transfer orbit.

That Tesla Roadster is something to see as well. Equipped with a mannequin named “Starman” after the 1972 David Bowie song, and a dashboard message of “Don’t Panic!” from the book Hitchhiker’s Guide to the Galaxy by Douglas Adams, the cherry red convertible is currently on a trajectory taking it past Mars, and on its way to orbit the sun. You can watch footage of it here.

After the success of the launch, two of the core boosters, designed to be reusable, returned to their designated areas in Cape Canaveral Air Force Station. The third was set to land on a landing pad in the Atlantic Ocean. It missed—taking out a drone ship nearby, and plunging into the water at 300 miles per hour. Despite this miscalculation, the test run was still a huge success for the future of space exploration and space travel.

“I think it’s going to open up a sense of possibility,” Musk was widely reported to have said after the launch. “We want a new space race. Space races are exciting.”

SpaceX is ready to lead the charge. With the success of the test run, the next steps include commercial satellite launches for the U.S. Air Force and a solar-sail mission for The Planetary Society. After that, SpaceX wants to send people to Mars as early as 2024.

“Crazy things can come true,” Musk added. “When I see a rocket lift off, I see a thousand things that could not work, and it’s amazing when they do.” Some of those amazing things working where they shouldn’t are undoubtedly because of the use of composites.

Magnum Venus Products is an innovator of composites, pumping and spraying equipment for closed/open molds, adhesives, and epoxies. MVP serves a multitude of manufacturers in a variety of industries such as automotive, aerospace, transportation, marine, railway, and oil & gas among many others. For more information on the great products MVP offers, visit the website!

Read more at mvpind.com

Spacex

Part of this channel

Spacex

Designing Rockets and Spacecraft for a Multiplanetary Future

Visit the channel

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Why ISPE put peptide and oligo facility design in one guide

Why ISPE put peptide and oligo facility design in one guide

ISPE's new Baseline Guide covers oligonucleotide and peptide facility design in one document, says Jim Love of CRB. It pairs a GMP survey of existing plants with a sustainability outlook and a piping safety framework for scale-up, while FDA's oligonucleotide guidances under dockets opened in 2022 and 2024 remain the regulator's own reference.

  • 01Peptide plants inherited API chemistry thinking and oligo plants biotech thinking; ISPE’s guide puts both modalities in one facility document with both inheritances.
  • 02The guide has three parts: a GMP survey of existing oligo and peptide plants, a forecast of how sustainability and scale will change the processes, and a safety framework for connective piping and equipment.
  • 03FDA keeps its own oligonucleotide-specific guidances under dockets opened in 2022 and 2024, so the ISPE guide works as an industry consensus alongside regulation rather than in place of it.

Nov 5, 2026

Collagen builder Astrion outdrew AstraGin at NuLiv's Bangkok booth

Collagen builder Astrion outdrew AstraGin at NuLiv's Bangkok booth

NuLiv Science says Astrion, its collagen-building ingredient, drew more interest than AstraGin at Vitafoods Asia 2026 in Bangkok, held September 2 to 4. Brands also asked for probiotic strains for pet weight loss, children and women's health. A newly published AstraGin trial in Nutrients and a July 2026 Senactiv trial give the company fresh evidence for its older ingredients.

  • 01At Vitafoods Asia 2026 in Bangkok, Astrion drew more booth interest than AstraGin, NuLiv’s absorption flagship.
  • 02NuLiv says probiotic requests are now split by pet, child and life stage, and the show preview lists strains for women’s health, emotional wellbeing and the gut-muscle axis.
  • 03A newly published crossover trial in Nutrients found AstraGin raised branched-chain amino acid absorption and grip strength in adults aged 60 to 80.

Nov 5, 2026

Astrion drew more interest than AstraGin at NuLiv Science's Bangkok booth

Astrion drew more interest than AstraGin at NuLiv Science's Bangkok booth

NuLiv Science reported from Vitafoods Asia 2026 in Bangkok that collagen-building Astrion drew more interest than AstraGin, its absorption ingredient, as collagen and anti-aging products are heavily marketed and sold in almost every store, a company representative said. A 150-person trial published in Cosmetics in June 2025 found oral Astrion raised skin collagen 13.2%. Mordor Intelligence still puts North America at 37.95% of collagen supplement revenue, with Asia-Pacific growing fastest at 11.65%.

  • 01NuLiv Science expected AstraGin to lead in a new market; at Vitafoods Asia 2026 in Bangkok, its collagen-boosting Astrion drew more attention, the company said.
  • 02Oral Astrion raised skin collagen content 13.2% over 12 weeks in a 150-person, placebo-controlled trial published in Cosmetics in June 2025.
  • 03North America still held 37.95% of collagen supplement revenue in 2025 while Asia-Pacific grows fastest at 11.65% a year, Mordor Intelligence estimates, so the Asian pull is a growth story rather than a size story.

Nov 5, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512